CoChat

Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay

Open access
Schwaederle, Maria, Husain, Hatim, Fanta, Paul T., Piccioni, David E., Kesari, Santosh, Schwab, Richard B., Banks, Kimberly C., Lanman, Richard B., Talasaz, AmirAli, Parker, Barbara A., Kurzrock, Razelle · 2016 · Oncotarget
Cited by 149

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

// Maria Schwaederle 1 , Hatim Husain 1 , Paul T. Fanta 1 , David E. Piccioni 1 , Santosh Kesari 1 , Richard B. Schwab 1 , Kimberly C. Banks 2 , Richard B. Lanman 2 , AmirAli Talasaz 2 , Barbara A. Parker 1 , Razelle Kurzrock 1 1 Center for Personalized Cancer Therapy and Division of Hematology and Oncology, UCSD Moores Cancer Center, La Jolla, CA, USA 2 Guardant Health, Inc., Redwood City, CA, USA Correspondence to: Maria Schwaederle, e-mail: mschwaederle@ucsd.edu Keywords: cancer, liquid biopsy, ctDNA, actionable alteration, personalized therapy Received: September 30, 2015 Accepted: January 23, 2016 Published: February 01, 2016 ABSTRACT Analysis of cell-free DNA using next-generation sequencing (NGS) is a powerful tool for the detection/monitoring of alterations present in circulating tumor DNA (ctDNA). Plasma extracted from 171 patients with a variety of cancers was analyzed for ctDNA (54 genes and copy number variants (CNVs) in three genes ( EGFR , ERBB2 and MET )). The most represented cancers were lung (23%), breast (23%), and glioblastoma (19%). Ninety-nine patients (58%) had at least one detectable alteration. The most frequent alterations were TP53 (29.8%), followed by EGFR (17.5%), MET (10.5%), PIK3CA (7%), and NOTCH1 (5.8%). In contrast, of 222 healthy volunteers, only one had an aberration ( TP53 ). Ninety patients with non-brain tumors had a discernible aberration (65% of 138 patients; in 70% of non-brain tumor patients with an alteration, the anomaly was potentially actionable). Interestingly, nine of 33 patients (27%) with glioblastoma had an alteration (6/33 (18%) potentially actionable). Overall, sixty-nine patients had potentially actionable alterations (40% of total; 69.7% of patients (69/99) with alterations); 68 patients (40% of total; 69% of patients with alterations), by a Food and Drug Administration (FDA) approved drug. In summary, 65% of diverse cancers (as well as 27% of glioblastomas) had detectable ctDNA aberration(s), with the majority theoretically actionable by an approved agent.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.7110

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 149

Metadata

Authors
Schwaederle, M., Husain, H., Fanta, P. T., Piccioni, D. E., Kesari, S., Schwab, R. B., Banks, K. C., Lanman, R. B., Talasaz, A., Parker, B. A., & Kurzrock, R.
Venue
Oncotarget
Published
2016-02-01
Volume
7
Issue
9
Pages
9707-9717
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2288310435
Cited by
149
References
11
FWCI
9.83
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay. https://app.cochat.ai/papers/10.18632/oncotarget.7110
The paper
Schwaederle, M., Husain, H., Fanta, P. T., Piccioni, D. E., Kesari, S., Schwab, R. B., Banks, K. C., Lanman, R. B., Talasaz, A., Parker, B. A., & Kurzrock, R. (2016). Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay. Oncotarget. https://doi.org/10.18632/oncotarget.7110

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.